Parecoxib vs. lornoxicam in the treatment of postoperative pain after laparoscopic cholecystectomy: A prospective randomized placebo-controlled trial

European Journal of Anaesthesiology

Volumn 24, Issue 2, 2007, Pages 154-158

  Papadima, A ^a   Lagoudianakis, E E ^a   Antonakis, P T ^a   Pattas, M ^a   Kremastinou, F ^a   Katergiannakis, V ^a   Manouras, A ^a   Georgiou, L ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Cholecystectomy laparoscopic; Lornoxicam; Pain acute and postoperative; Parecoxib; Surgery, abdominal

Indexed keywords

LORNOXICAM; MIDAZOLAM; ONDANSETRON; PARECOXIB; PETHIDINE; PLACEBO; PROPOFOL; REMIFENTANIL; ROCURONIUM;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLEEDING; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HUMAN; LAPAROSCOPIC SURGERY; MALE; MOTION; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; REST; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLECYSTECTOMY, LAPAROSCOPIC; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOXAZOLES; MALE; MEPERIDINE; MIDDLE AGED; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PIROXICAM; PLACEBOS; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, ELECTIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846120457     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021506001293     Document Type: Article

References (22)

1. Bisgaard T, Klarskov B, Rosenberg J, Kehlet H. Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 2001; 90: 261-269.
2. Joshi GP, Viscusi ER, Gan TJ et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 2004; 98: 336-342.
3. Ng A, Temple A, Smith G, Emembolu J. Early analgesic effects of parecoxib versus ketorolac following laparoscopic sterilization: a randomized controlled trial. Br J Anaesth 2004; 92: 846-849.
4. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 2003; 3: 1.
5. Gan TJ, Joshi GP, Zhao SZ, Hanna DB, Cheung RY, Chen C. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol Scand 2004; 48: 1194-1207.
6. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-1928.
7. Goldstein JL, Correa P, Zhao WW et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96: 1019-1027.
8. Harris SI, Stoltz RR, LeComte D, Hubbard RC. Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects. J Clin Gastroenterol 2004; 38: 575-580.
9. Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003; 43: 504-513.
10. Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am J Emerg Med 2002; 20: 275-281.
11. Gan TJ, Joshi GP, Viscusi E et al. Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 2004; 98: 1665-1673.
12. Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003; 63: 33-45.
13. McMurray RW, Hardy KJ. Cox-2 inhibitors: today and tomorrow. Am J Med Sci 2002; 323: 181-189.
14. Balfour JA, Fitton A, Barradell LB. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639-657.
15. Bombardier C, Laine L, Reicin A et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
16. Meagher EA. Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 2004; 10: 603-611.
17. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-1091.
18. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005; 42: 312-324.
19. Slappendel R, Weber EW, Benraad B, Dirksen R, Bugter ML. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol 2002; 19: 829-831.
20. Møiniche S, Rømsing J, Dahl JB, Tramèr MR. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Analg 2003; 96: 68-77.
21. Desikan SR, Meena NG. Do non-steroidal anti-inflammatory drugs increase the risk of bleeding after tonsillectomy? Arch Dis Child 2004; 89: 493-494.
22. Noveck RJ, Hubbard RC. Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters. J Clin Pharmacol 2004; 44: 474-480.